Skip to main content
. Author manuscript; available in PMC: 2018 Mar 13.
Published in final edited form as: Muscle Nerve. 2016 May 19;54(2):284–291. doi: 10.1002/mus.25048

FIGURE 1.

FIGURE 1

Disease progression. (A) In disease-relevant mice harboring the SOD1G93A mutation, there was decreased hindlimb grip strength in statin- vs. vehicle-treated mice [n = 8–13 per group; F(1, 38) = 11.44, P = 0.002]; decreased hindlimb grip strength in H67D Hfe vs. WT Hfe mice [F(1, 38) = 13.67, P < 0.001]; and decreased hindlimb grip strength over time [F(5, 172) = 22.48, P < 0.001]. There was an interaction between Hfe status and time, with grip strength decreasing faster over time in SOD1G93A mice vs. double transgenic mice [F(5, 172) = 4.64, P < 0.001]. (B) In disease-relevant mice harboring the SOD1G93A mutation, there was a trend toward decreased forelimb grip strength in statin- vs. vehicle-treated mice [n = 8–13 per group; F(1, 38) = 3.83, P = 0.058]; decreased forelimb grip strength in H67D Hfe vs. WT Hfe mice [F(1, 38) = 11.32, P = 0.002]; and decreased forelimb grip strength over time [F(5, 172) = 29.98, P < 0.001].